Reduction of pro-inflammatory cytokines in rats following 7-day oral supplementation with a proprietary eggshell membrane-derived product

Kevin Ruff, Dale P. DeVore

Modern Research in Inflammation · 2014 · 35 citations · 15 references

DOIFull text

Open access

Concepts

Abstract

brand eggshell membrane is a novel dietary supplement that has been clinically shown to alleviate arthritis joint pain and stiffness; however the mechanism of action is not well understood. Preliminary evidence from an in vitro study of NEM indicated that the mechanism of action may be based on the reduction of pro-inflammatory cytokines. In vivo studies were therefore initiated to evaluate the effects of NEM on pro-inflammatory and anti-inflammatory cytokines following oral administration in rats. NEM was administered daily at doses of 6. Inflammation was induced in the Study 3 rats by intraperitoneal injection of lipopolysaccharide. Changes in plasma cytokine levels from baseline following 7 days of oral supplementation with NEM at 6.13 mg/kg bw/ day (Study 1) were statistically significant at Day 8 for IL-2, TIMP-1 and VEGF, at Day 21 for IL-10, and at Day 35 for MCP-1, MCP-3 and TIMP-1, and at 10.0 mg/kg bw/day (Study 2) were statistically significant at Day 8 for VEGF, at Day 21 for MIP-1, MIP-2 and VEGF, and at Day 35 for MCP-3, MIP-1, MIP-2 and VEGF. Changes in serum cytokine levels versus control at 26.0 mg/kg bw/day (Study 3) were statistically significant at all time-points for IL-1 and at 1.5 hours for IL-10, and at 52.0 mg/kg bw/day (Study 3) were statistically significant at 1.5 hours for IFN-, IL-1 and IL-10, and at 3 hours for IL-1, and at 24 hours for IL-10. Taken together, these studies demonstrate that oral supplementation with NEM can influence both early-phase proinflammatory cytokines like IL-1 and TNF- (Study 3), as well as later-phase cytokines like MCP-1, MIP-1 & , RANTES and VEGF (Study 1 & 2). These studies provide a possible basis for the mechanism of action of NEM in vivo.

References

15